Document is current

Article History

Accepted: 19 September 2020

First Online: 18 November 2020

Declarations

:

: No funding was received for the conduct of this study or the preparation of this article.

: Raquel Freitas, Fátima Godinho, Nathalie Madeira, Bruno Miguel Fernandes, Flávio Costa, Mariana Santiago, Agna Neto, Soraia Azevedo, Maura Couto, Graça Sequeira, João Madruga Dias, and Luís Miranda have no conflicts of interest that are directly relevant to the content of this study. Miguel Bernardes is on the advisory boards of Lilly, Biogen, and Abbvie (fees < $10,000). Joaquim Polido-Pereira is on the advisory boards of Pfizer, MSD, and Abbvie (fees < $10,000). João Eurico Fonseca receives consultancy and speaking fees for Pfizer, UCB, Jansen, Roche, MSD, Novartis, Abbvie, and Lilly (fees < $10,000). Maria José Santos receives consultancy and speaking fees for Pfizer and Abbvie (fees < $10,000).

: Reuma.pt was approved by the National Data Protection Authority and the ethics committee of each participating center. This study was approved by the Ethics Committee of Hospital Garcia de Orta, Almada, Portugal.

: All patients registered in the database Reuma.pt provided written informed consent for data collection and analysis.

: All patients registered in the database Reuma.pt provided written informed consent for publication.

: The database generated and analyzed during the study is not publicly available due to ethical and law restrictions. The data that support the findings of this study are available on request from the corresponding author.

: Not applicable.

: The study protocol and analysis plan was drafted by R Freitas and MJ Santos and revised by all the authors. Data analyses and draft of the manuscript were done by R Freitas. All authors contributed substantially for study conception, data acquisition and interpretation, revised the final manuscript for important intellectual content and approved the final version submitted for publication.